A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS
Immuno Cure appoints new CFO
Strengthening of executive management team to propel growth strategy
Immuno Cure secured maximum subsidy from HKSTP
Significant funding support for HIV Vaccine Clinical Trial
Immuno Cure BioTech acquires Shanghai Teresa Healthcare
Integrating Electroporation Technology & DNA Vaccine Platforms
Acquisition of 92.6% of Shanghai Teresa Healthcare
Immuno Cure BioTech appoints new CEO
Broadening executive leadership team to accelerate growth strategy
Dr. Xia Jin appointed as new Chief Executive Officer and Executive Director of our Group
HKUMed discovers a novel vaccine strategy to prevent SARS-CoV-2 nasal infection
The study demonstrated that a combination of intramuscular PD1-based receptor-binding domain (RBD) DNA vaccine (PD1-RBD-DNA) prime and intranasal live attenuated influenza-based vaccine (LAIV-HK68-RBD) boost vaccination regimen induced the strongest mucosal broadly neutralising antibodies and lung resident memory CD8 T cells, which prevented live SARS-CoV-2 nasal challenges in two animal models